Zydus Lifesciences Limited has launched PEPAIR™, marking a major milestone as India’s first affordable Oscillating Positive Expiratory Pressure (OPEP) device. With this launch, the company aims to bridge a critical gap in respiratory care by offering a drug-free, handheld solution designed to improve breathing for patients with chronic respiratory conditions.
Product Features and Affordable Pricing
PEPAIR™ features a patented three-resistance system specifically engineered to support effective mucous clearance and reduce airway congestion. By helping patients clear accumulated mucus, the device promotes easier breathing and improved respiratory function.
Importantly, Zydus has adopted a patient-centric pricing strategy. The device is available at Rs. 990 per unit, making OPEP therapy more accessible to a broader patient population.
Product Specifications:
- Device Name: PEPAIR™
- Price: Rs. 990 per unit
- Type: Oscillating Positive Expiratory Pressure (OPEP) device
- Design: Drug-free, handheld device with patented 3-resistance system
- Target Conditions: COPD, asthma, bronchiectasis
Addressing a Growing Respiratory Health Burden
As reported by scanx.trade, the launch comes at a time when India faces a significant burden of chronic respiratory diseases, affecting over 90 lakh patients. Conditions such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and bronchiectasis often lead to chronic mucous hypersecretion, which requires regular airway clearance.
Although clinical guidelines recommend OPEP-based airway clearance therapy, limited affordability has historically restricted access for many patients. Therefore, PEPAIR™ directly addresses this unmet need by offering a cost-effective and practical solution for everyday respiratory care.
How OPEP Therapy Works
OPEP therapy uses a handheld device that generates controlled pressure and vibrations during exhalation. These oscillations loosen mucus, open airways, and promote effective clearance. As a result, patients experience reduced airway obstruction, fewer coughing episodes, and improved overall respiratory comfort.
Notably, PEPAIR™ operates without pharmaceutical intervention. Consequently, it serves as a valuable non-drug addition to long-term respiratory disease management, complementing existing inhalation and oral therapies.
Leadership Perspective
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, highlighted the company’s focus on accessible innovation.
“At Zydus, patient-centric innovation means advancing healthcare in ways that make everyday care more accessible. With PEPAIR™, India’s first affordable OPEP device, we are introducing a drug-free, handheld solution designed to support better breathing for patients with COPD, asthma, and bronchiectasis.”
Strategic Collaboration with AeroDel
The launch represents a strategic collaboration between Zydus Lifesciences and AeroDel Technology Innovations Pvt. Ltd. AeroDel, an Indian medical device company specializing in inhalation and pulmonary rehabilitation technologies, developed the underlying OPEP platform and serves as the manufacturing partner for PEPAIR™.
Through this partnership, the companies have combined pharmaceutical expertise with medical device innovation to deliver a practical respiratory care solution.
Strengthening Zydus’ Respiratory Leadership
Zydus continues to strengthen its position as one of India’s leading respiratory care companies. The company commands a strong presence in oral and inhalation therapies and leads the oral bronchodilator segment with Deriphyllin, one of India’s most prescribed methylxanthines.
Moreover, its respiratory portfolio spans:
- Inhaled Corticosteroid (ICS) + Long-Acting Beta2-Agonist (LABA) combinations
- LABA + Long-Acting Muscarinic Antagonist (LAMA) formulations
- Single Inhaler Triple Therapy (SITT) solutions
- Once-daily triple therapies such as Odihale G and Umiflo Plus
The company has also pioneered key innovations in respiratory medicine, including the introduction of LABA+LAMA therapy with Forglyn and the advancement of Single Inhaler Triple Therapy with Forglyn Plus.
Expanding Access to Everyday Respiratory Care
With the launch of PEPAIR™, Zydus Lifesciences expands its respiratory portfolio beyond pharmaceuticals into device-based care. By combining affordability, innovation, and patient-focused design, the company aims to make airway clearance therapy more accessible—ultimately improving daily respiratory health outcomes across India.